Ranibizumab — Discount Pricing

Other medications in Ophthalmology

• Tafluprost
• Timolol
• Timolol Ophthalmic
• Travoprost
• Tropicamide
• Verteporfin
• Acetazolamide
• Aflibercept

About Ranibizumab

Ranibizumab is a critical medication used to treat serious eye conditions that can lead to vision loss. By targeting specific proteins, it helps preserve sight for many patients. Understanding this vital treatment and its costs is key, and TheDrugClub is dedicated to helping our members access essential prescriptions like ranibizumab more affordably.

Ranibizumab is a specialized medication administered via injection directly into the eye, primarily used to combat various conditions that threaten central vision. These include wet age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Each of these conditions involves damage to the macula, the part of the retina responsible for sharp, central vision, making ranibizumab a crucial tool in preventing severe vision impairment or blindness.

How Ranibizumab Works to Preserve Vision

At its core, ranibizumab is an anti-vascular endothelial growth factor

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ranibizumab is approved for (FDA label)

SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ).

Source: Read the full FDA label on DailyMed. Label effective date: November 21, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ranibizumab (FDA label)

WARNING: ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. [see Contraindications (4.1) , Warnings and Precautions (5.1) ] . WARNING: ENDOPHTHALMITIS See full prescribing information for complete boxed warning. The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

Source: FDA prescribing information (DailyMed). Set ID: 9c6d9e2a-9a77-4d11-b692-de87cfde3444. SPL document ID: 2850382e-4e4f-4005-a047-33fc758bafef. Label effective date: November 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ranibizumab (FDA label)

Injection: 100 mg/mL, clear to slightly opalescent, colorless to slightly brownish solution in a single-dose vial Injection: 100 mg/mL solution in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 9c6d9e2a-9a77-4d11-b692-de87cfde3444. SPL document ID: 2850382e-4e4f-4005-a047-33fc758bafef. Label effective date: November 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ranibizumab (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the label: Endophthalmitis [see Warnings and Precautions (5.1) ] Rhegmatogenous Retinal Detachment [see Warnings and Precautions (5.2) ] Implant Dislocation [see Warnings and Precautions (5.3) ] Septum Dislodgement [see Warnings and Precautions (5.4) ] Vitreous Hemorrhage [see Warnings and Precautions (5.5) ] Conjunctival Erosion or Retraction [see Warnings and Precautions (5.6) ] Conjunctival Bleb [see Warnings and Precautions (5.7) ] Postoperative Decrease in Visual Acuity [see Warnings and Precautions (5.8) ] The most common adverse reactions (≥ 10%) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract and vitreous hemorrhage. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 9c6d9e2a-9a77-4d11-b692-de87cfde3444. SPL document ID: 2850382e-4e4f-4005-a047-33fc758bafef. Label effective date: November 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ranibizumab (FDA label)

Ocular or periocular infections ( 4.1 ) Active intraocular inflammation ( 4.2 ) Hypersensitivity ( 4.3 ) 4.1 Ocular or Periocular Infections SUSVIMO (ranibizumab injection) is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation SUSVIMO (ranibizumab injection) is contraindicated in patients with active intraocular inflammation. 4.3 Hypersensitivity SUSVIMO (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in SUSVIMO (ranibizumab injection).

Source: FDA prescribing information (DailyMed). Set ID: 9c6d9e2a-9a77-4d11-b692-de87cfde3444. SPL document ID: 2850382e-4e4f-4005-a047-33fc758bafef. Label effective date: November 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.